John Friend, MD, CEO of Kazia Therapeutics added, "The novelty of the science that Professor Rao has proposed with this dual ...

The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency ...

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, discusses how MMRF ...

Recent survey study of 978 cancer patients and their relatives uncovered reasons behind their willingness, or lack thereof, ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, talks unmet need in ...

Research from the Tufts Center for the Study of Drug Development’s PACT Consortium shows DCTs encourage higher participation ...

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, highlights the ...

In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...

Initiatives to Establish Capabilities in Early Phase Clinical Research in Malaysia ...

Initiatives to Establish Capabilities in Early Phase Clinical Research in Malaysia ...

Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response ...